Theravance Biopharma, a pharmaceutical company based in the United States, is currently facing an investor probe over a deal that raised concerns among shareholders. The deal in question involved the sale of the company’s biopharmaceutical royalties to a private equity firm for $1.25 billion.
Investors have raised questions about the terms of the deal and whether it was in the best interest of the company and its shareholders. Some are concerned that the sale of the royalties may have undervalued the assets and deprived shareholders of potential future returns.
The investigation into the deal is ongoing, with regulators looking into the details of the transaction and whether appropriate measures were taken to ensure transparency and fairness for all parties involved. The outcome of the probe could have significant implications for Theravance Biopharma and its investors, as well as potentially impacting the broader pharmaceutical industry.
For more details and the full reference, visit the source link below:
Read the complete article here: https://www.stl.news/theravance-biopharma-deal-faces-investor-probe/